West Pharmaceutical Services, Inc. $WST Shares Sold by Brown Advisory Inc.

Posted by Francis Steltz on Jun 14th, 2026

Brown Advisory Inc. lowered its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 22.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 1,943,606 shares of the medical instruments supplier’s stock after selling 554,476 shares during the quarter. Brown Advisory Inc.’s holdings in West Pharmaceutical Services were worth $534,771,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in WST. Empowered Funds LLC increased its stake in shares of West Pharmaceutical Services by 16.1% in the 1st quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier’s stock valued at $361,000 after purchasing an additional 224 shares in the last quarter. Intech Investment Management LLC increased its stake in shares of West Pharmaceutical Services by 27.7% in the 1st quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier’s stock valued at $1,348,000 after purchasing an additional 1,307 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of West Pharmaceutical Services by 14.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier’s stock valued at $284,000 after purchasing an additional 157 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of West Pharmaceutical Services by 78.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier’s stock valued at $98,000 after purchasing an additional 197 shares in the last quarter. Finally, First Trust Advisors LP increased its stake in shares of West Pharmaceutical Services by 168.4% in the 2nd quarter. First Trust Advisors LP now owns 46,332 shares of the medical instruments supplier’s stock valued at $10,137,000 after purchasing an additional 29,067 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

Analyst Upgrades and Downgrades

WST has been the subject of several recent analyst reports. Morgan Stanley lifted their price target on West Pharmaceutical Services from $315.00 to $325.00 and gave the company an “equal weight” rating in a research note on Friday, May 29th. Barclays upgraded West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $310.00 to $400.00 in a report on Tuesday. Citigroup reiterated a “buy” rating on shares of West Pharmaceutical Services in a report on Friday, April 24th. Wolfe Research assumed coverage on West Pharmaceutical Services in a report on Monday, June 1st. They issued an “outperform” rating and a $375.00 price objective on the stock. Finally, Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, April 27th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, West Pharmaceutical Services currently has an average rating of “Buy” and an average target price of $340.09.

View Our Latest Stock Report on West Pharmaceutical Services

Insider Activity at West Pharmaceutical Services

In other news, CAO Chad Winters sold 896 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the transaction, the chief accounting officer directly owned 1,523 shares in the company, valued at $457,920.41. The trade was a 37.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Annette F. Favorite sold 2,817 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $305.20, for a total value of $859,748.40. Following the transaction, the vice president owned 16,828 shares in the company, valued at approximately $5,135,905.60. This represents a 14.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.60% of the company’s stock.

West Pharmaceutical Services Trading Down 0.6%

WST stock opened at $328.33 on Friday. The stock has a market cap of $23.20 billion, a price-to-earnings ratio of 43.89, a PEG ratio of 2.75 and a beta of 1.18. The business’s 50-day moving average is $298.97 and its 200 day moving average is $271.63. West Pharmaceutical Services, Inc. has a 12-month low of $206.80 and a 12-month high of $336.82. The company has a current ratio of 2.71, a quick ratio of 2.04 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST – Get Free Report) last issued its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.45. The business had revenue of $844.90 million for the quarter, compared to analysts’ expectations of $779.68 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The business’s revenue for the quarter was up 21.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, sell-side analysts anticipate that West Pharmaceutical Services, Inc. will post 8.6 EPS for the current fiscal year.

West Pharmaceutical Services declared that its Board of Directors has authorized a stock buyback program on Tuesday, February 17th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical instruments supplier to purchase up to 5.6% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its stock is undervalued.

West Pharmaceutical Services Company Profile

(Free Report)

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.